These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34794819)

  • 21. Disease Burden of Invasive Meningococcal Disease in the Netherlands Between June 1999 and June 2011: A Subjective Role for Serogroup and Clonal Complex.
    Stoof SP; Rodenburg GD; Knol MJ; Rümke LW; Bovenkerk S; Berbers GA; Spanjaard L; van der Ende A; Sanders EA
    Clin Infect Dis; 2015 Oct; 61(8):1281-92. PubMed ID: 26123933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular characterization of invasive serogroup B Neisseria meningitidis isolates from Spain during 2015-2018: Evolution of the vaccine antigen factor H binding protein (FHbp).
    Abad R; García-Amil C; Navarro C; Martín E; Martín-Díaz A; Vázquez JA
    J Infect; 2021 Apr; 82(4):37-44. PubMed ID: 33610688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduction in Neisseria meningitidis infection in Italy after Meningococcal C conjugate vaccine introduction: A time trend analysis of 1994-2012 series.
    de Waure C; Miglietta A; Nedovic D; Mereu G; Ricciardi W
    Hum Vaccin Immunother; 2016; 12(2):467-73. PubMed ID: 26308192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of Meningococcal Vaccines at Reducing Invasive Meningococcal Disease and Pharyngeal Neisseria meningitidis Carriage: A Systematic Review and Meta-analysis.
    McMillan M; Chandrakumar A; Wang HLR; Clarke M; Sullivan TR; Andrews RM; Ramsay M; Marshall HS
    Clin Infect Dis; 2021 Aug; 73(3):e609-e619. PubMed ID: 33212510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidemiology of serogroup C and Y invasive meningococcal disease (IMD) in Ontario, 2000-2013: Vaccine program impact assessment.
    Wormsbecker AE; Wong K; Jamieson FB; Crowcroft NS; Deeks SL
    Vaccine; 2015 Oct; 33(42):5678-5683. PubMed ID: 26299749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidemiology of invasive meningococcal B disease in Australia, 1999-2015: priority populations for vaccination.
    Archer BN; Chiu CK; Jayasinghe SH; Richmond PC; McVernon J; Lahra MM; Andrews RM; McIntyre PB;
    Med J Aust; 2017 Nov; 207(9):382-387. PubMed ID: 29092704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic Similarity of Gonococcal Homologs to Meningococcal Outer Membrane Proteins of Serogroup B Vaccine.
    Marjuki H; Topaz N; Joseph SJ; Gernert KM; Kersh EN; ; Wang X
    mBio; 2019 Sep; 10(5):. PubMed ID: 31506309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic evaluation of meningococcal serogroup B (MenB) vaccines: A systematic review.
    Nwogu IB; Jones M; Langley T
    Vaccine; 2021 Apr; 39(16):2201-2213. PubMed ID: 33744052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents.
    Carr J; Plested E; Aley P; Camara S; Davis K; MacLennan JM; Gray S; Faust SN; Borrow R; Christensen H; Trotter C; Maiden MCJ; Finn A; Snape MD;
    BMJ Open; 2020 Oct; 10(10):e037358. PubMed ID: 33093030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Invasive meningococcal disease in Chile seven years after ACWY conjugate vaccine introduction.
    Villena R; Valenzuela MT; Bastías M; Santolaya ME
    Vaccine; 2022 Jan; 40(4):666-672. PubMed ID: 34996641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of an Immunization Campaign to Control an Increased Incidence of Serogroup B Meningococcal Disease in One Region of Quebec, Canada.
    De Wals P; Deceuninck G; Lefebvre B; Tsang R; Law D; De Serres G; Gilca V; Gilca R; Boulianne N
    Clin Infect Dis; 2017 May; 64(9):1263-1267. PubMed ID: 28207068
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Economic evaluation of the introduction of 4CMenB (Bexsero®) in the national vaccine schedule in Spain].
    Ruiz-Montero R; Epstein D; Guzmán Herrador B; Espín Balbino J
    Gac Sanit; 2020; 34(4):318-325. PubMed ID: 31776044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genomic Characterization of Invasive Meningococcal Serogroup B Isolates and Estimation of 4CMenB Vaccine Coverage in Finland.
    Bodini M; Brozzi A; Giuliani M; Nohynek H; Vainio A; Kuusi M; De Paola R; Pizza M; Medini D; Toropainen M; Serino L; Muzzi A
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proceedings of the Expert Consensus Group meeting on meningococcal serogroup B disease burden and prevention in India.
    Dubey AP; Hazarika RD; Abitbol V; Kolhapure S; Agrawal S
    Hum Vaccin Immunother; 2022 Dec; 18(1):2026712. PubMed ID: 35239455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular typing of group B Neisseria meningitidis'subcapsular antigens directly on biological samples demonstrates epidemiological congruence between culture-positive and -negative cases: A surveillance study of invasive disease over a 13-year period.
    Lodi L; Moriondo M; Nieddu F; Ricci S; Guiducci S; Lippi F; Canessa C; Calistri E; Citera F; Giovannini M; Indolfi G; Resti M; Azzari C
    J Infect; 2021 Apr; 82(4):28-36. PubMed ID: 33610687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. First statewide meningococcal B vaccine program in infants, children and adolescents: evidence for implementation in South Australia.
    Marshall HS; Lally N; Flood L; Phillips P
    Med J Aust; 2020 Feb; 212(2):89-93. PubMed ID: 31909501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Meningococcal invasive disease by serogroup W and use of ACWY conjugate vaccines as control strategy in Chile.
    Villena R; Valenzuela MT; Bastías M; Santolaya ME
    Vaccine; 2019 Oct; 37(46):6915-6921. PubMed ID: 31585728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost calculator for mass vaccination response to a US college campus outbreak of serogroup B meningococcal disease.
    La EM; Talbird SE; Kanadanian KV; Huang L; Fain J; Srivastava A
    Hum Vaccin Immunother; 2019; 15(4):978-986. PubMed ID: 30526279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A critical analysis of serogroup B meningococcal disease burden in Brazil (2001-2015): implications for public health decisions.
    Chicuto LAD; de Moraes C; Cássio de Moraes J; Sáfadi MAP
    Hum Vaccin Immunother; 2020 Aug; 16(8):1945-1950. PubMed ID: 31951784
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Burden of Pediatric Invasive Meningococcal Disease in Spain (2008-2013).
    Rivero-Calle I; Vilanova-Trillo L; Pardo-Seco J; Salvado LB; Quinteiro LI; Martinon-Torres F;
    Pediatr Infect Dis J; 2016 Apr; 35(4):407-13. PubMed ID: 26974748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.